168899-58-9

Usage

Uses

Used in Pharmaceutical Industry:
3-Acetoxy-o-toluic acid is used as a chemical intermediate for the synthesis of small-sized HIV protease inhibitors, which are crucial in the development of antiretroviral medications to combat HIV/AIDS. Its role in the synthesis process is vital for creating effective treatments that can help manage the progression of the disease and improve the quality of life for those affected.

InChI:InChI=1/C10H10O4/c1-6-8(10(12)13)4-3-5-9(6)14-7(2)11/h3-5H,1-2H3,(H,12,13)

Upstream product

• 603-80-5 3-hydroxy 2-methylbenzoic acid 
• 1975-50-4 2-methyl-3-nitrobenzic acid 
• 10533-44-5 trisodium 1,3,5-naphthalenetrisulfonate 
• 108-24-7 acetic anhydride 

Downstream Products

• 1053258-94-8 Acetic acid 3-[(1S,2S)-1-benzyl-3-((R)-4-tert-butylcarbamoyl-thiazolidin-3-yl)-2-hydroxy-3-oxo-propylcarbamoyl]-2-methyl-phenyl ester 
• 1054648-28-0 acetic acid 3-{(1S,2S)-1-benzyl-3-[(4R)-5,5-dimethyl-4-(2-methyl-benzylcarbamoyl)-thiazolidin-3-yl]-2-hydroxy-3-oxo-propylcarbamoyl}-2-methyl-phenyl ester 
• 1054625-99-8 Acetic acid 3-[(1S,2S)-1-benzyl-3-((R)-4-benzylcarbamoyl-thiazolidin-3-yl)-2-hydroxy-3-oxo-propylcarbamoyl]-2-methyl-phenyl ester 
• 1053738-50-3 Acetic acid 3-{(1S,2S)-1-benzyl-2-hydroxy-3-[(R)-4-(3-methyl-benzylcarbamoyl)-thiazolidin-3-yl]-3-oxo-propylcarbamoyl}-2-methyl-phenyl ester 
• 1053646-81-3 Acetic acid 3-{(1S,2S)-1-benzyl-3-[(R)-4-(2-chloro-benzylcarbamoyl)-5,5-dimethyl-thiazolidin-3-yl]-2-hydroxy-3-oxo-propylcarbamoyl}-2-methyl-phenyl ester 
• 1055039-07-0 Acetic acid 3-{(1S,2S)-1-benzyl-3-[(R)-4-(2,6-dimethyl-benzylcarbamoyl)-thiazolidin-3-yl]-2-hydroxy-3-oxo-propylcarbamoyl}-2-methyl-phenyl ester 
• 1053259-52-1 Acetic acid 3-{(1S,2S)-1-benzyl-3-[(R)-5,5-dimethyl-4-(2-trifluoromethyl-benzylcarbamoyl)-thiazolidin-3-yl]-2-hydroxy-3-oxo-propylcarbamoyl}-2-methyl-phenyl ester 
• 521275-18-3 acetic acid 3-(N'-benzyl-hydrazinocarbonyl)-2-methyl-phenyl ester 
• 767341-31-1 Acetic acid 3-[(R)-1-((S)-2,2-dimethyl-[1,3]dioxolan-4-yl)-2-phenylsulfanyl-ethylcarbamoyl]-2-methyl-phenyl ester 
• 690223-69-9 (-)-(3S,4aS,8aS,2'R,3'R) acetic acid 3-[3'-(3-tert-butylcarbamoyl-decahydro-isoquinolin-2-yl)-2'-hydroxy-1'-(thiophen-2-yl)-propylcarbamoyl]-2-methyl-phenyl ester 

Relevant academic research and scientific papers

Method of making HIV protease inhibitors

A method of making HIV protease inhibitors of general formula (1): These HIV compounds inhibit or block the biological activity of the HIV protease enzyme, causing the replication of the HIV virus to terminate. These compounds, as well as pharmaceutical compositions that contain these compounds and optically other antiviral agents as active ingredients, are suitable for treating patients or hosts infected with the HIV virus, which is known to cause AIDS.

Process to prepare 3-acyloxy-2-methyl-benzoic acid

Die Erfindung betrifft ein verbessertes Verfahren zur Herstellung von 3-Acyloxy-2-methylbenzoes?uren durch Erhitzen von substituierten Naphthalinen in Gegenwart von Alkalimetallhydroxiden und anschlie?ender Acylierung.

Synthesis and biological evaluation of CX-659S and its related compounds for their inhibitory effects on the delayed-type hypersensitivity reaction

In order to find novel nonsteroidal compounds possessing an inhibitory activity against delayed-type hypersensitivity (DTH) reactions, we conducted random screening using a picryl chloride (PC)-induced contact hypersensitivity reaction (CHR) in mice, and found compound 1 as a lead compound. Then we synthesized and evaluated an extensive series of 5-carboxamidouracil derivatives focused on both the uracil and the antioxidative moieties. Among them, we found that the hindered phenol moiety was necessary to exhibit the activities; especially, compounds 28a-28c having the partial structure of vitamin E were found to exert potent activities against the DTH reaction by both oral and topical administration. And compound 28c showed antioxidative activity against lipid peroxidation with an IC50 of 5.9μM. Compound 28c (CX-659S) was chosen as a candidate drug for the treatment of cutaneous disorders such as atopic dermatitis and allergic contact dermatitis. Copyright (C) 2000 Elsevier Science Ltd.

Process for producing amide derivatives and intermediates therefor

PCT No. PCT/JP96/02756 Sec. 371 Date Apr. 14, 1998 Sec. 102(e) Date Apr. 14, 1998 PCT Filed Sep. 24, 1996 PCT Pub. No. WO97/11937 PCT Pub. Date Apr. 3, 1997A method for producing an amide derivative of the formula [XV] wherein each symbol is as defined in the specification, and an enantiomer thereof, a novel intermediate useful for producing said compound and a production method thereof. The production method of the present invention is extremely easy and simple as compared to the conventional methods, and enables effective production of compound [XV] at high yields, which includes compound [XVI] having an HIV protease inhibitory action. In addition, the novel intermediates of the present invention are extremely useful as intermediates for producing not only the aforementioned compound [XVI] but also compounds useful as X-ray contrast media.

Process for the preparation of 3-acetoxy-2-methylbenzoyl chloride

The present invention relates to a process for the preparation of 3-acetoxy-2-methylbenzoyl chloride by reacting an alkali metal salt of 3-aminonaph-thalene-1,5-disulfonic acid with alkali metal hydroxide and water in the weight ratio 1:(1 to 1.6):(1 to 1

Process for the preparation of 3-hydroxy-2-methylbenzoic acid and 3-acetoxy-2-methylbenzoic

The invention relates to a process for the preparation of 3-hydroxy-2-methylbenzoic acid and 3-acetoxy-2-methylbenzoic acid, which comprises reacting 3-chloro-2-methylphenol (3) with benzyl chloride to give 2-benzyloxy-6-chlorotoluene (4) subjecting this

HIV protease inhibitors

HIV protease inhibitors, obtainable by chemical synthesis, inhibit or block the biological activity of the HIV protease enzyme, causing the replication of the HIV virus to terminate. These compounds, as well as pharmaceutical compositions that contain these compounds and optionally other anti-viral agents as active ingredients, are suitable for treating patients or hosts infected with the HIV virus, which is known to cause AIDS.

HIV protease inhibitors

HIV protease inhibitors, obtainable by chemical synthesis, inhibit or block the biological activity of the HIV protease enzyme, causing the replication of the HIV virus to terminate. These compounds, as well as pharmaceutical compositions that contain these compounds and optionally other anti-viral agents as active ingredients, are suitable for treating patients or hosts infected with the HIV virus, which is known to cause AIDS.